Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcomeMichael J. Campbell, Laura J. Esserman, Nathan Tonlaar et al.|Breast Cancer Research and Treatment|2010Cited by 265
Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breastMichael J. Campbell, Laura J. Esserman, Alfred Au et al.|Breast Cancer Research and Treatment|2016Cited by 110
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I. Gallagher, Emanuel F. Petricoin, Julia Wulfkuhle et al.|Cell Reports Medicine|2023Cited by 18
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injectionAlexa Glencer, Michael J. Campbell, Jasmine Wong et al.|npj Breast Cancer|2021Cited by 12
Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.Julia Wulfkuhle, Christina Yau, Denise M. Wolf et al.|Journal of Clinical Oncology|2019Cited by 11